151 related articles for article (PubMed ID: 1417069)
1. Etretinate or cyclosporin-A treatment normalizes the enhanced respiratory burst of polymorphonuclear leukocytes in psoriasis.
Schopf RE; Höcher J; Rehder M; Färber L; Morsches B
Arch Dermatol Res; 1992; 284(4):227-31. PubMed ID: 1417069
[TBL] [Abstract][Full Text] [Related]
2. Eosinophils, pruritus and psoriasis: effects of treatment with etretinate or cyclosporin-A.
Schopf RE; Hultsch T; Lotz J; Bräutigam M
J Eur Acad Dermatol Venereol; 1998 Nov; 11(3):234-9. PubMed ID: 9883435
[TBL] [Abstract][Full Text] [Related]
3. Stimulus-dependent increased generation of oxygen intermediates in monocytes and polymorphonuclear leukocytes in psoriasis.
Schopf RE; Straussfeld E
J Invest Dermatol; 1985 Jan; 84(1):73-6. PubMed ID: 3965581
[TBL] [Abstract][Full Text] [Related]
4. Low-dose short-term cyclosporine versus etretinate in psoriasis: improvement of skin, nail, and joint involvement.
Mahrle G; Schulze HJ; Färber L; Weidinger G; Steigleder GK
J Am Acad Dermatol; 1995 Jan; 32(1):78-88. PubMed ID: 7822521
[TBL] [Abstract][Full Text] [Related]
5. Cyclosporin versus etretinate: Italian multicenter comparative trial in severe plaque-form psoriasis. Italian Multicenter Study Group on Cyclosporin in Psoriasis.
Dermatology; 1993; 187 Suppl 1():8-18. PubMed ID: 8369579
[TBL] [Abstract][Full Text] [Related]
6. Etretinate therapy reduces polymorphonuclear leukocyte chemotaxis--enhancing properties of psoriatic serum.
Ellis CN; Kang S; Grekin RC; Voorhees JJ; Silva J
J Am Acad Dermatol; 1985 Sep; 13(3):437-43. PubMed ID: 4056118
[TBL] [Abstract][Full Text] [Related]
7. Etretinate therapy for psoriasis. Reduction of antibody-dependent cell-mediated cytotoxicity of polymorphonuclear leukocytes.
Ellis CN; Kang S; Grekin RC; LoBuglio AF; Voorhees JJ
Arch Dermatol; 1985 Jul; 121(7):877-80. PubMed ID: 4015133
[TBL] [Abstract][Full Text] [Related]
8. Increased respiratory burst activity of monocytes and polymorphonuclear leukocytes in psoriasis.
Schopf RE; Altmeyer P; Lemmel EM
Br J Dermatol; 1982 Nov; 107(5):505-10. PubMed ID: 6751372
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the therapeutic range of whole blood cyclosporin concentration in the treatment of psoriasis.
Ieiri I; Nakayama J; Murakami H; Hori Y; Higuchi S
Int J Clin Pharmacol Ther; 1996 Mar; 34(3):106-11. PubMed ID: 8705088
[TBL] [Abstract][Full Text] [Related]
10. A highly decreased binding of cyclic adenosine monophosphate to protein kinase A in erythrocyte membranes is specific for active psoriasis.
Schopf RE; Langendorf Y; Benz RE; Färber L; Benes P
J Invest Dermatol; 2002 Jul; 119(1):160-5. PubMed ID: 12164939
[TBL] [Abstract][Full Text] [Related]
11. Acitretin versus etretinate in psoriasis. Clinical and pharmacokinetic results of a German multicenter study.
Gollnick H; Bauer R; Brindley C; Orfanos CE; Plewig G; Wokalek H; Hoting E
J Am Acad Dermatol; 1988 Sep; 19(3):458-68. PubMed ID: 2971692
[TBL] [Abstract][Full Text] [Related]
12. The effects of retinoids and terbinafine on the human hepatic microsomal metabolism of cyclosporin.
Shah IA; Whiting PH; Omar G; Ormerod AD; Burke MD
Br J Dermatol; 1993 Oct; 129(4):395-8. PubMed ID: 8217751
[TBL] [Abstract][Full Text] [Related]
13. Etretinate modulates the leukotriene B4 induced intra-epidermal accumulation of polymorphonuclear leukocytes.
Lammers AM; van de Kerkhof PC
Br J Dermatol; 1987 Sep; 117(3):297-300. PubMed ID: 2823858
[TBL] [Abstract][Full Text] [Related]
14. Effects of systemic etretinate treatment on natural cytotoxicity, immune angiogenesis and neutrophil adherence in patients with various forms of psoriasis.
Majewski S; Wolska H; Jabłońska S; Wasik M
Arch Immunol Ther Exp (Warsz); 1989; 37(3-4):459-64. PubMed ID: 2484150
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of cyclosporine plus etretinate in the treatment of erythrodermic psoriasis (three case reports).
Kokelj F; Plozzer C; Torsello P; Trevisan G
J Eur Acad Dermatol Venereol; 1998 Sep; 11(2):177-9. PubMed ID: 9784049
[TBL] [Abstract][Full Text] [Related]
16. A double-blind comparison of acitretin and etretinate in the treatment of severe psoriasis. Results of a Nordic multicentre study.
Kragballe K; Jansén CT; Geiger JM; Bjerke JR; Falk ES; Gip L; Hjorth N; Lauharanta J; Mork NJ; Reunala T
Acta Derm Venereol; 1989; 69(1):35-40. PubMed ID: 2563606
[TBL] [Abstract][Full Text] [Related]
17. Clinical trial of the efficacy and safety of oral etretinate with calcipotriol cream compared with etretinate alone in moderate-severe psoriasis.
Giannetti A; Coppini M; Bertazzoni MG; Califano A; Altieri E; Pazzaglia A; Lega M; Lombardo M; Pelfini C; Veller Fornasa C; Rabbiosi G; Cespa M
J Eur Acad Dermatol Venereol; 1999 Sep; 13(2):91-5. PubMed ID: 10568486
[TBL] [Abstract][Full Text] [Related]
18. Differential effects of cyclosporine and etretinate on serum cytokine levels in patients with psoriasis.
Shiohara T; Imanishi K; Sagawa Y; Nagashima M
J Am Acad Dermatol; 1992 Oct; 27(4):568-74. PubMed ID: 1401309
[TBL] [Abstract][Full Text] [Related]
19. Oral cyclosporin in psoriasis: a systematic review on treatment modalities, risk of kidney toxicity and evidence for use in non-plaque psoriasis.
Maza A; Montaudié H; Sbidian E; Gallini A; Aractingi S; Aubin F; Bachelez H; Cribier B; Joly P; Jullien D; Le Maître M; Misery L; Richard MA; Ortonne JP; Paul C
J Eur Acad Dermatol Venereol; 2011 May; 25 Suppl 2():19-27. PubMed ID: 21388455
[TBL] [Abstract][Full Text] [Related]
20. Cyclosporin A in combination with photochemotherapy (PUVA) in the treatment of psoriasis.
Petzelbauer P; Hönigsmann H; Langer K; Anegg B; Strohal R; Tanew A; Wolff K
Br J Dermatol; 1990 Nov; 123(5):641-7. PubMed ID: 2248892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
